This Notice was RESCINDED on December 9, 2016, please see NOT-DE-17-008 that replaces it.

RESCINDED

RESCINDED - Notice of Participation of the National Institute of Dental and Craniofacial Research (NIDCR) in PA-15-106 "Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R21)"

Notice Number: NOT-DE-17-004

Key Dates
Release Date:  November 23, 2016 (Rescinded December 9, 2016)

Related Announcements
NOT-DE-17-008
PA-15-106

Issued by
National Institute on Dental and Craniofacial Research (NIDCR)

Purpose

This Notice is to inform potential applicants that the National Institute of Dental and Craniofacial Research (NIDCR) is participating, effective immediately, in PAR-15-106 "Health Disparities and Alzheimer's Disease (R21)".

The following sections of PAR-15-106 have been updated to reflect the participation of NIDCR in this Funding Opportunity Announcement (FOA).

Part 1. Overview Information

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.855, 93.856, 93.121

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

 

Research Objectives

FOA currently reads:

The objective of this research program is to promote the identification of novel HIV biomarkers that can be used to develop HIV incidence assays or algorithms with improved specificity. Such biomarkers might be based on evolution of specific viral parameters or host responses in the first year after HIV infection.  Additionally, method development for utilizing the biomarker(s) to identify incident cases in a highly accurate, cost effective assay will be supported. 

FOA is modified to read (modification in italics):
The objective of this research program is to promote the identification of novel HIV biomarkers that can be used to develop HIV incidence assays or algorithms with improved specificity. Such biomarkers might be based on evolution of specific viral parameters or host responses in the first year after HIV infection.  Additionally, method development for utilizing the biomarker(s) to identify incident cases in a highly accurate, cost effective assay will be supported. 

NIDCR is interested in applications that aim to identify and characterize biomarkers from oral biospecimens, e.g. saliva, oral swabs, that can serve as incidence markers for HIV infection.  NIDCR does not support clinical trials through this FOA. 

Section VII. Agency Contacts

Scientific/Research Contact(s)

Gallya Gannot, DMD, PhD
National Institute on Dental and Craniofacial Research (NIDCR)
Telephone: 301-451-5096
Email: gallya.gannot@nih.gov

Financial/Grants Management Contact(s)

Diana Rutberg, MBA
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone: 301-594-4798
Email: rutbergd@mail.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Gallya Gannot, DMD, PhD
National Institute on Dental and Craniofacial Research (NIDCR)
Telephone: 301-451-5096
Email: gallya.gannot@nih.gov